Alerts
Myeloma Patients May Not Need Treatment Forever
The ENDURANCE trial found no overall survival benefit from indefinite lenalidomide maintenance compared with stopping after two years in standard-risk, newly diagnosed multiple myeloma patients who did not undergo transplant. This is a de-escalation story with real cost and quality-of-life consequences.
Stroke Rehab Cannot Stop at Survival
Disaster Shelters Save Lives. Infection Control Cannot Be Improvised.
China’s Biliary-Cancer Bet Has a Global Access Problem
MS Regulators Are No Longer Reading the Same Risk
NTDs Are Now A Human-Rights Issue. Budgets Must Follow.
A CE Mark Is Not Access
Europe Opens the SMA Gene-Therapy Door Wider
The Transplant Is Not the Finish Line
For Pompe Infants, Time Is the Comparator
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.